

NEWS

FOR IMMEDIATE RELEASE:

The GI Company to Present at the BIO 2008 International Convention

Dr. Nicholas Barker Featured in Exclusive Interview on PharmaVenturesTv

Framingham, MA – June 2, 2008 – The GI Company, Inc., a privately held developer of gastrointestinal therapeutics, today announced that Nicholas Barker, Ph.D., President and Chief Executive Officer, will make a corporate presentation on June 18 at 2:45 PM PST in room 3 at the *BIO 2008 International Convention* taking place June 17-20, 2008 in San Diego, CA. Dr. Barker will also participate in the BIO Business Forum and be available for one-on-one meetings during the convention. His presentation will include a summary of results from a Phase II clinical study designed to evaluate the safety and efficacy of the company's lead clinical candidate, Intestinal Trefoil Factor (rhITF), in development for the prophylaxis of chemotherapy-induced oral mucositis. These data were presented in peer review at the *American Society of Clinical Oncology (ASCO) 2008 Annual Meeting*. For more information, visit <http://www.bio2008.org/>

PharmaVenturesTv

In this exclusive interview, Fintan Walton, the anchor of *PharmaVenturesTv*, talks to Dr. Barker about the company's academic origins, its key technologies and financial sources. Dr. Barker also provides details about the company's lead Phase II clinical candidate, Intestinal Trefoil Factor (rhITF). Dr. Barker also discusses additional clinical applications for rhITF, as well as partnering opportunities for the company's product development candidates. The interview can be viewed by following this link: <http://www.pharmatelevision.com/article/interview89>

About The GI Company, Inc.

The GI Company is a clinical-stage biotechnology company highly specialized at developing drugs to treat gastrointestinal and related diseases. The company's lead clinical candidate is Intestinal Trefoil Factor (rhITF) which is being developed for the treatment of oral mucositis. The GI Company also has clinical rhITF programs in a variety of conditions such as erosive gastritis (NSAID induced), ulcerative colitis and corneal wound healing as well as pre-clinical development projects in Enteritis/Proctitis, Inflammatory Bowel Disease, Erosive Gastroesophageal Reflux Disease, Peptic Ulcer Disease and gastrointestinal motility disorders. The company is funded through a private equity financing consortium and has raised over \$20M to date. The GI Company has retained Burrill & Company to assist in the selection of a transaction partner for its clinical programs. For more information, please visit www.thegicompany.com

Contact:

Tim Allison

LaVoie Group

978.745.4200 x 102

tallison@lavoigroup.com